Clinical Trials Logo

Hyperaldosteronism clinical trials

View clinical trials related to Hyperaldosteronism.

Filter by:

NCT ID: NCT05658705 Recruiting - Clinical trials for Primary Aldosteronism

Preoperative Supine Time for Adrenal Venous Sampling

PSTAVS
Start date: March 29, 2023
Phase: N/A
Study type: Interventional

This study aim to understand whether the length of preoperative supine time would affect the AVS outcome.

NCT ID: NCT05640128 Recruiting - Clinical trials for Hyperaldosteronism; Primary

Determination of Threshold Values of Aldosterone in HPLC-MS/MS, of Renin and of the Aldosterone / Renin Ratio for the Diagnosis of Primary Hyperaldosteronism

DAPS
Start date: January 2, 2018
Phase: N/A
Study type: Interventional

collaborative work within 2 hospitals at the CHU of Caen, at the CHRU of Lille, concerning the evaluation of the biological markers of primary hyperaldosteronism (PAH) with the dosage of aldosterone in LC -MS/MS, which is performed in both centers, with two different techniques. The main objective is to define the range of Aldosterone concentrations in LC MS/MS, of renin in an automated method, in populations of healthy volunteers, essential hypertensives, and hypertensives with primary hyperaldosteronism. , in order to establish a threshold for the screening of PAH by the RAR, and for the confirmation of PAH by a dynamic test with an Aldosterone threshold post salt load test.

NCT ID: NCT05638269 Recruiting - Lung Cancer Clinical Trials

A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China

Start date: March 1, 2022
Phase:
Study type: Observational

The human gut microbiome has been associated with many health factors but variability between studies limits the exploration of effects between them. This study aims to systematically characterize the gut microbiota of various critical chronic diseases, compare the similarities and differences of the microbiome signatures linked to different regions and diseases, and further investigate their impacts on microbiota-based diagnostic models.

NCT ID: NCT05636995 Recruiting - Clinical trials for Hypertensive Disorder of Pregnancy

HyperAldosteronism in Pregnancy Predicted Impacts (H.A.P.P.I. Trial)

Start date: January 10, 2023
Phase:
Study type: Observational [Patient Registry]

Primary hyperaldosteronism confers a higher risk of cardiovascular complications compared to essential hypertension. Preliminary data is controversial in regards of excessive maternal fetal and neonatal excessive risks in pregnancy. This study aims at establishing the prevalence of PHA in an population with a recent episode of hypertensive disorder of pregnancy (HDP). The goal is to determine if a universal screening for PHA after a HDP is worthed. The investigators also wish to evaluate the complication rate in pregnant women with PHA compared to women without PHA. This is a prospective cohort study where all eligible women will be screened for PHA after a HDP episode in the last pregnancy. We will then compare PHA women to non PHA women according to pregnancy complications.

NCT ID: NCT05561361 Recruiting - Clinical trials for Primary Aldosteronism

The Effect of SAAE on Vascular Endothelial Function in PA Patients

Start date: October 1, 2022
Phase:
Study type: Observational

The study aims to assess the effect of superselective adrenal arterial embolization on vascular endothelial function in patients with primary aldosteronism based on brachial artery flow-mediated relaxation

NCT ID: NCT05501080 Recruiting - Clinical trials for Primary Aldosteronism

The Effect of SAAE on Ventricular Remodeling in PA Patients

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The study aims to assess the effect of superselective adrenal arterial embolization on ventricular remodeling in primary aldosteronism without lateralized aldosterone secretion by comparing it with spironolactone therapy.

NCT ID: NCT05405101 Recruiting - Clinical trials for Primary Aldosteronism

Randomised Trial Comparing Thermal Ablation With Adrenalectomy in the Treatment of Unilateral Asymmetric PA

WAVE
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The primary objective of WAVE is to test the hypothesis that thermal ablation (microwave or RFA) is non-inferior to surgery in the biochemical (and if so, in the clinical) cure of unilateral PA, according to the international consensus PASO criteria. Secondary objectives are to determine whether either intervention is superior to the other in relation to the following outcomes. Where no superiority of either intervention is established, non-inferiority of thermal ablation against adrenalectomy will be sought. - Frequency and severity of adverse events - Length of inpatient stay - Patient satisfaction - Quality of life - Return to activities of daily living An additional secondary objective in the thermal ablation group alone will be anatomical efficacy of ablation.

NCT ID: NCT05368090 Recruiting - Clinical trials for Primary Aldosteronism

Endoscopic Ultrasound-guided Radiofrequency Ablation in Primary Aldosteronism

Start date: June 3, 2022
Phase: N/A
Study type: Interventional

In this study, the investigators will perform endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) treatment of left-sided adrenal tumours in patients with primary aldosteronism (PA) and in patients with mild autonomous cortisol secretion (MACS). Four different study groups will all receive EUS-RFA of left-sided adrenal tumours. Clinical and biochemical outcome as well as procedural safety will be evaluated. In study patients with verified lateralised aldosterone or cortisol overproduction to the left adrenal, outcome will be compared with control groups performing conventional unilateral adrenalectomy. Study group 1: PA patients with AVS-verified left sided lateralisation and a EUS-detectable tumour in the left adrenal for EUS-RFA treatment. Study group 2: PA patient with suspected left-sided overweight of aldosterone production and a EUS-detectable tumour but without strict lateralisation of their aldosterone overproduction, for EUS-RFA treatment as an aldosterone "debulking" procedure. Study group 3: patients with MACS with AVS-verified lateralisation of cortisol overproduction to the left adrenal and EUS-detectable tumour for EUS-RFA treatment Study group 4: patients with MACS with bilateral adrenal tumours and verified bilateral overproduction of cortisol for EUS-RFA treatment as a cortisol "debulking" procedure.

NCT ID: NCT05232162 Recruiting - Aldosteronism Clinical Trials

Establishment of Aldosterone and Renin Reference Range

ARR
Start date: December 15, 2021
Phase:
Study type: Observational

Elevated aldosterone levels were also shown to contribute to the excess morbidity and mortality. Literature shows aldosterone and renin levels differ between ethnicity and gender. There is no established reference intervals for these two hormone levels in Asian community. We aim to establish reference intervals for plasma aldosterone and direct renin concentrations among Malaysians residing in Sarawak using the chemiluminescent immunoassay (CLIA). This is a cross-sectional study which will be conducted among ambulatory patients, healthy blood donors and healthy volunteers. 300 participants who fulfil study criteria will be recruited after informed consent. Socio-demographic data and anthropometric measurements will be recorded. Blood will be taken for plasma aldosterone, renin, serum potassium and creatinine. Urine will be collected for estimation of 24-hour sodium excretion. Aldosterone and renin reference intervals will be established partitioned for gender.

NCT ID: NCT05188872 Recruiting - Clinical trials for Positron-Emission Tomography

Application of 68Ga-Pentixafor PET/CT in Primary Aldosteronism and Pre-postoperative of SAAE

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

Primary aldosteronism is the most common cause of secondary hypertension. The two main types of primary aldosteronism are aldosteronoma(30%) and adrenal hyperplasia(60%). The gold standard that determines the diagnosis and treatment strategy of primary aldosteronism is adrenal vein sampling(AVS), but the success rate is only about 80%. Using CXCR4 as a probe for 68Ga-Pentixafor PET/CT imaging can guide the classification diagnosis and treatment strategy of primary aldosteronism, which is a favorable supplement to AVS. Superselective adrenal artery embolization(SAAE) and laparoscopy are the main operation treatments for primary aldosteronism. SAAE is an invasive interventional operation. It is a novel way to evaluate the changes in the structure and function of adrenal tissue pre-postoperative SAAE by using the changes in 68Ga-Pentixafor PET/CT imaging.